ETROPAIN 90 TAB is an advanced pharmaceutical formulation developed to address chronic and acute inflammatory conditions through the potent action of Etoricoxib 90 mg, a selective cyclooxygenase-2 (COX-2) inhibitor. Etoricoxib functions by specifically targeting the COX-2 enzyme, which is responsible for the synthesis of prostaglandins that mediate inflammation, pain, and fever. Unlike traditional non-selective NSAIDs, Etoricoxib spares COX-1, which plays a role in gastric mucosal protection, thereby minimizing gastrointestinal irritation and ulceration.

This selective mechanism of action makes ETROPAIN 90 TAB ideal for long-term management of pain and inflammation in conditions such as osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis (AS), and acute gouty arthritis. It is also effective in treating moderate pain associated with dental or orthopedic procedures. The 90 mg dosage is particularly suited for patients requiring consistent anti-inflammatory action without compromising gastrointestinal safety.

BluepillExpress manufactures ETROPAIN 90 TAB using pharmaceutical-grade Etoricoxib API sourced from certified vendors. The formulation is produced under stringent quality assurance protocols in accordance with international GMP norms. Each batch undergoes comprehensive quality testing for assay, dissolution, microbial load, and stability parameters to ensure efficacy and shelf-life consistency.

Pharmacokinetically, Etoricoxib is well absorbed after oral administration, with peak plasma concentrations typically reached within one hour. It exhibits a high degree of plasma protein binding and is extensively metabolized by the liver. The elimination half-life ranges from 22 to 26 hours, allowing for once-daily dosing, which enhances patient compliance in chronic therapy.

ETROPAIN 90 TAB is administered orally and may be taken with or without food. The recommended dosage varies depending on the indication: for osteoarthritis and ankylosing spondylitis, 60–90 mg daily is typical; for acute gout, 120 mg may be used for short-term flare management. Physicians may adjust the dose based on severity of symptoms and patient tolerance.

Clinical studies have demonstrated that Etoricoxib offers comparable or superior pain relief to other NSAIDs like diclofenac or naproxen, with fewer adverse effects on the gastrointestinal tract. However, because it may increase cardiovascular risk in susceptible patients, its use should be carefully monitored, particularly in those with a history of hypertension, ischemic heart disease, or renal dysfunction.

ETROPAIN 90 TAB is contraindicated in patients with known hypersensitivity to Etoricoxib or sulfonamides, active peptic ulceration, advanced hepatic impairment, inflammatory bowel disease, or severe congestive heart failure. It should be avoided in the third trimester of pregnancy and is not recommended for use in pediatric populations.

Common side effects include headache, dizziness, dyspepsia, peripheral edema, and elevated liver enzymes. Rare but serious adverse events can include myocardial infarction, stroke, and anaphylactic reactions. Therefore, patient selection and periodic monitoring of blood pressure, renal function, and hepatic enzymes are advised during long-term use.